Catalog & Gene Editing

Effortlessly access and evaluate our premium cell banks of iPSCs edited with our exclusive proprietary modifications, available in both research and clinical grades, all from a single, reliable source.

Allogeneic cell-based therapies hold significant promise for treating currently incurable diseases.

However, two major challenges arise: the risk of immune rejection when using cells from allogeneic donors and concerns regarding the safety of gene-engineered therapeutic cells within the patient’s body. 

To tackle these challenges, Pluristyx offers the solution of our genetic engineering expertise and proprietary technologies. The panCELLa platform includes an innovative gene-editing platform that utilizes CRISPR- and transposon-based gene editing approach to engineer universal donor cells with a safety-switch technology. 

These universal donor cells can be used in allogeneic cell therapy development without the need for individualized matching and provide an external control to eliminate the therapeutic cells in case of unexpected adverse events or to address potential safety concerns.

What types of gene edits can Pluristyx apply to cells?

Pluristyx’s pioneering proprietary technology, FailSafe®, empowers the editing and engineering of cells to enhance safety. By introducing a “kill switch,” this patented innovation can halt uncontrolled proliferation within cells. Notably, FailSafe® operates on cell division loci while preserving the inherent biological characteristics of the edited cells.
induced allogeneic cell tolerance iACT Stealth Cells™

induced allogeneic cell tolerance (iACT) Stealth Cells™, enables the creation of induced pluripotent stem cells (iPSCs) that avoid provoking an immune response in the recipient and help ensure long-term allograft tolerance. By targeting eight specific cell-surface and local-acting genes that modulate the immune response, iACT Stealth Cells™ function as universal donors well suited for off-the-shelf regenerative medicine therapies without the need for patients to undergo immunosuppressive treatments in advance.

Broad Portfolio of Custom Edits

Besides FailSafe® and iACT Stealth Cells™, Pluristyx can also offer a broad portfolio of custom edits, ranging from knocking in/out genes, gene insertion, conditional regulation of expression, and immortalization. Pluristyx’s team has experience with various gene editing technologies. All edited cells are assessed with various quality control tests to ensure the highest quality standards are met

Explore More

REA Process & Licensing

Try Before You Buy
By offering the Research Evaluation Agreement you can gain access to our modified and non-modified cellular products for evaluation with our Try Before You Buy model. A smaller upfront payment limits your risk. Once you see the successful results, you can then enter into a license agreement with us panCELLa / Pluristyx.
Learn More

Cellular Reprogramming

Proprietary Footprint-Free RNA Reprogramming Method to Generate iPSCs
Pluristyx’s iPSCs are produced using mRNA, engineered to increase the level of protein/transcription factor expression and facilitate the reprogramming of somatic cells into induced pluripotent stem cells. Pluristyx’s iPSC have been shown to differentiate into a wide range of cell types.
Learn more
Contact us to learn more about our gene engineering experience and how we can help you

Scroll to Top